SELECT * FROM `stock_list` WHERE `symbol` = "EIGRQ" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) ORDER BY delisted ASC limit 0,1
SELECT * FROM `stock_list` where symbol='EIGRQ' AND exchange = 'OTCPK' ORDER BY delisted ASC limit 0,1
SELECT * FROM `stock_list` WHERE `symbol` = "EIGRQ" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) ORDER BY delisted ASC limit 0,1 EIGRQ (Eiger BioPharmaceuticals) Gross Margin %
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eiger BioPharmaceuticals Inc (OTCPK:EIGRQ) » Definitions » Gross Margin %

Eiger BioPharmaceuticals (Eiger BioPharmaceuticals) Gross Margin % : 97.34% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Eiger BioPharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Eiger BioPharmaceuticals's Gross Profit for the three months ended in Dec. 2023 was $3.70 Mil. Eiger BioPharmaceuticals's Revenue for the three months ended in Dec. 2023 was $3.80 Mil. Therefore, Eiger BioPharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was 97.34%.


The historical rank and industry rank for Eiger BioPharmaceuticals's Gross Margin % or its related term are showing as below:

EIGRQ' s Gross Margin % Range Over the Past 10 Years
Min: 86.38   Med: 93.86   Max: 99.85
Current: 99.85


During the past 13 years, the highest Gross Margin % of Eiger BioPharmaceuticals was 99.85%. The lowest was 86.38%. And the median was 93.86%.

EIGRQ's Gross Margin % is ranked better than
98.1% of 735 companies
in the Biotechnology industry
Industry Median: 59.43 vs EIGRQ: 99.85

Eiger BioPharmaceuticals had a gross margin of 97.34% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Eiger BioPharmaceuticals was 0.00% per year.


Eiger BioPharmaceuticals Gross Margin % Historical Data

The historical data trend for Eiger BioPharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eiger BioPharmaceuticals Gross Margin % Chart

Eiger BioPharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 93.86 86.38 99.85

Eiger BioPharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 87.20 97.13 106.68 96.42 97.34

Competitive Comparison of Eiger BioPharmaceuticals's Gross Margin %

For the Biotechnology subindustry, Eiger BioPharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eiger BioPharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eiger BioPharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Eiger BioPharmaceuticals's Gross Margin % falls into.



Eiger BioPharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Eiger BioPharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=15.7 / 15.773
=(Revenue - Cost of Goods Sold) / Revenue
=(15.773 - 0.023999999999999) / 15.773
=99.85 %

Eiger BioPharmaceuticals's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=3.7 / 3.803
=(Revenue - Cost of Goods Sold) / Revenue
=(3.803 - 0.101) / 3.803
=97.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Eiger BioPharmaceuticals  (OTCPK:EIGRQ) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Eiger BioPharmaceuticals had a gross margin of 97.34% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Eiger BioPharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Eiger BioPharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Eiger BioPharmaceuticals (Eiger BioPharmaceuticals) Business Description

Traded in Other Exchanges
Address
2155 Park Boulevard, Palo Alto, CA, USA, 94306
Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
Executives
Richard A Kayne 10 percent owner
Leen Kawas 10 percent owner 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Ingrid Choong officer: Chief Business Officer 24645 SUMMERHILL AVE, LOS ALTOS CA 94024
William G Kachioff officer: CFO 4060 PORTE DE PALMAS, SAN DIEGO CA 92122
James Vollins officer: General Counsel C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE SUITE 225, RALEIGH NC 27607
Mayer Eldon C. Iii officer: Ex VP & Chief Commerc. Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Lisa Kelly-croswell director C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Thomas John Dietz director C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804
Jeffrey S Glenn director 350 CAMBRIDGE AVENUE, SUITE 350, PALO ALTO CA 94306
David Apelian director C/O ACHILLION PHARMACEUTICALS, INC, 300 GEORGE STREET, NEW HAVEN CT 06511
Sriram Ryali officer: Chief Financial Officer C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Christine Murray director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Erik Atkisson officer: GC & Chief Compliance Officer C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Kim Sablich director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
David A Cory director, officer: President and CEO 350 CAMBRIDGE AVENUE, SUITE 350, PALO ALTO CA 94306